USE OF IL-20 ANTAGONISTS FOR ALLEVIATING SPINAL CORD INJURY

Ming-Shi Chang (Inventor)

Research output: Patent

Abstract

Alleviating neural injury, such as spinal cord injury, in a subject (e.g., a human subject) in need of the treatment using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20. Such antibodies include anti-IL-20 antibodies and anti-IL-20R antibodies that specifically block the IL-20 signaling pathway.
Original languageEnglish
Patent number9512218
Publication statusPublished - 1800

Fingerprint

Spinal Cord Injuries
Anti-Idiotypic Antibodies
Antibodies
interleukin 20
Wounds and Injuries

Cite this

@misc{58e115ff68ed4d83870bf0fdf38204c7,
title = "USE OF IL-20 ANTAGONISTS FOR ALLEVIATING SPINAL CORD INJURY",
abstract = "Alleviating neural injury, such as spinal cord injury, in a subject (e.g., a human subject) in need of the treatment using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20. Such antibodies include anti-IL-20 antibodies and anti-IL-20R antibodies that specifically block the IL-20 signaling pathway.",
author = "Ming-Shi Chang",
year = "1800",
language = "English",
type = "Patent",
note = "9512218",

}

TY - PAT

T1 - USE OF IL-20 ANTAGONISTS FOR ALLEVIATING SPINAL CORD INJURY

AU - Chang, Ming-Shi

PY - 1800

Y1 - 1800

N2 - Alleviating neural injury, such as spinal cord injury, in a subject (e.g., a human subject) in need of the treatment using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20. Such antibodies include anti-IL-20 antibodies and anti-IL-20R antibodies that specifically block the IL-20 signaling pathway.

AB - Alleviating neural injury, such as spinal cord injury, in a subject (e.g., a human subject) in need of the treatment using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20. Such antibodies include anti-IL-20 antibodies and anti-IL-20R antibodies that specifically block the IL-20 signaling pathway.

M3 - Patent

M1 - 9512218

ER -